Biotech Industry Intelligence

Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win

Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win

Published

3 weeks ago

on

Pfizer said a combination of two of its prostate cancer drugs — Talzenna and Xtandi — succeeded in a Phase 3 study and that it plans to ask regulators for earlier use of Talzenna, a PARP inhibitor …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version